BioCentury
ARTICLE | Clinical News

Xilonix: Phase II data

November 5, 2012 8:00 AM UTC

Interim data from an open-label, Swiss Phase II trial in 7 Type II diabetics with an average baseline HbA1c of 7.4% showed that MABp1 reduced HBA1c by 0.2% by week 8. XBiotech said the reduction with MABp1 by week 8 was significantly more rapid than that observed with linagliptin monotherapy, which did not show the same 0.2% reduction in HbA1c until week 24 according to the company. Patients received 1.25 mg/kg IV MABp1 every 2 weeks for 8 weeks. Based on the interim data, XBiotech closed enrollment in the trial and plans to start a double-blind, placebo-controlled Phase IIb trial early next year evaluating a subcutaneous formulation of MABp1 in the indication. ...